11. June 2020

Hope for patients with advanced prostate cancer

The first patient to undergo lutetium-177-PSMA therapy at the University Hospital Basel was treated on 25 May. This makes USB the first Swiss hospital to produce and use lutetium-177-PSMA for the in-house treatment of advanced metastatic prostate cancer.

 

Alongside skin tumours, prostate cancer is the most common malignant tumour in Europe and the second most common cause of death in men. A promising new treatment method for advanced prostate cancer is now available at the University Hospital Basel.
 
With lutetium-177-PSMA therapy, the radioactive substance lutetium-177 is bound to a carrier substance (PSMA), which carries the radioactive element specifically to tumour cells of the prostate cancer. The first treatment with lutetium-177-PSMA in Basel means that patients with advanced metastatic prostate cancer at USB have a therapy available that is likely to be more effective than previous treatment options. Numerous patients with prostate cancer develop a metastatic form of the disease as well as resistance to the hormone therapy initially applied. So far, it has only been possible to treat patients with follow-on therapies of limited effectiveness. The results of various studies show that targeted therapy with 177Lu-PSMA is an additional effective option for such patients. For radiation protection reasons, 177Lu-PSMA therapy must be performed on the Nuclear Medicine ward and is paid for by the health insurance company.
 
The Nuclear Medicine Clinic of the University Hospital Basel, experienced in the development and application of radionuclide therapy, is one of the first institutes in Switzerland to be able to carry out this therapy. In Switzerland, only Radiopharmaceutical Chemistry at USB is currently able to produce the required therapeutic substance 177Lu-PSMA itself.
 
The patient treated on 25 May is currently doing well; he was able to leave the hospital after 3 days.

Contact:

Nuclear Medicine Secretariat: Tel.: +41 61 265 47 04, email: Therapie-NUK@anti-clutterusb.ch
Urological Tumour Centre Secretariat: Tel.: +41 61 328 56 60
Oncology contact: Tel.: +41 61 265 50 74